Last reviewed · How we verify
Placebo-acetazolamide
Acetazolamide inhibits carbonic anhydrase to reduce aqueous humor production and intraocular pressure, while the placebo component serves as a control in clinical evaluation.
Acetazolamide inhibits carbonic anhydrase to reduce aqueous humor production and intraocular pressure, while the placebo component serves as a control in clinical evaluation. Used for Glaucoma and ocular hypertension.
At a glance
| Generic name | Placebo-acetazolamide |
|---|---|
| Also known as | Diamox. Drug and placebo are prepared in similar capsules. |
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Acetazolamide is a carbonic anhydrase inhibitor that decreases aqueous humor secretion in the eye, thereby lowering intraocular pressure. The 'placebo-acetazolamide' designation suggests this is a formulation or study design combining active drug with placebo control, likely used in comparative clinical trials. This combination approach allows for assessment of acetazolamide's true efficacy against placebo baseline.
Approved indications
- Glaucoma and ocular hypertension
Common side effects
- Paresthesia
- Altered taste
- Increased urination
- Hypokalemia
- Metabolic acidosis
Key clinical trials
- Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment (PHASE4)
- Managing Opioid Related Sleep Apnea With Acetazolamide (PHASE2)
- Preoperative Acetazolamide (PHASE4)
- HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men (PHASE4)
- Acetazolamide on REM OSA (PHASE1, PHASE2)
- Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health (PHASE2)
- Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder (PHASE2)
- Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-acetazolamide CI brief — competitive landscape report
- Placebo-acetazolamide updates RSS · CI watch RSS
- Shahid Beheshti University of Medical Sciences portfolio CI